Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

9.6K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Sex-linked Disorders01:43

Sex-linked Disorders

102.3K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
102.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Psychosocial outcomes of reproductive genetic carrier screening up to five years post-result.

European journal of human genetics : EJHG·2026
Same author

Examining Epilepsy in Angelman Syndrome: Insights From Caregiver-Reported Data in the Linking Angelman and Dup15q Data for Expanded Research Database.

Pediatric neurology·2026
Same author

CMIP as a novel candidate gene for neurodevelopmental and neuropsychiatric disorders.

European journal of human genetics : EJHG·2026
Same author

Scoping review and recommendations for development and delivery of education resources for reproductive genetic carrier screening.

European journal of human genetics : EJHG·2026
Same author

Australian parents' perspectives on extended genomic screening: what information to return and when?

European journal of human genetics : EJHG·2026
Same author

Psychosocial outcomes of reproductive genetic carrier screening up to five years post-result.

European journal of human genetics : EJHG·2026

Related Experiment Video

Updated: Jul 15, 2025

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

7.9K

Insight and Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference

Flora Tassone1,2, Dragana Protic3,4, Emily Graves Allen5

  • 1Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.

Cells
|September 28, 2023
PubMed
Summary

Fragile X premutation (FMR1) involves CGG repeat expansion, leading to toxic FMR1 mRNA and RAN proteins. Understanding these molecular mechanisms is key for diagnosing and managing fragile X-premutation-associated conditions (FXPAC).

Keywords:
FMR1 molecular and clinicalFMR1 premutationFXANDFXPACFXPOIFXTAS

More Related Videos

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
11:10

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation

Published on: July 6, 2022

2.3K
Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
10:59

Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein

Published on: June 6, 2025

407

Related Experiment Videos

Last Updated: Jul 15, 2025

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

7.9K
Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
11:10

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation

Published on: July 6, 2022

2.3K
Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
10:59

Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein

Published on: June 6, 2025

407

Area of Science:

  • Genetics
  • Molecular Biology
  • Neuroscience

Background:

  • The Fragile X messenger ribonucleoprotein 1 (FMR1) gene premutation is defined by CGG trinucleotide repeat expansion (55-200 repeats).
  • This expansion leads to elevated FMR1 mRNA levels and various molecular disruptions.
  • These disruptions contribute to a spectrum of fragile X-premutation-associated conditions (FXPAC).

Purpose of the Study:

  • To summarize known molecular and clinical aspects of the FMR1 gene premutation.
  • To detail the presentations and discussions from the 2023 International Premutation Conference.
  • To emphasize the importance of understanding FXPAC for diagnosis, counseling, and management.

Main Methods:

  • Review of molecular mechanisms including R-loop formation, mRNA toxicity, and RAN-initiated translation.
  • Clinical characterization of phenotypes associated with FMR1 premutation.
  • Synthesis of findings presented at the International Premutation Conference.

Main Results:

  • Identified molecular mechanisms: R-loop formation, FMR1 mRNA toxicity (nuclear foci, protein sequestration), and RAN-initiated translation.
  • Clinical manifestations encompass Fragile X-associated tremor/ataxia syndrome (FXTAS), Fragile X-associated primary ovarian insufficiency (FXPOI), and Fragile X-associated neuropsychiatric disorders (FXAND).
  • These diverse issues collectively fall under the umbrella of FXPAC.

Conclusions:

  • Understanding the molecular basis of FMR1 premutation is crucial for accurate diagnosis and management of FXPAC.
  • Comprehensive knowledge of FXPAC facilitates genetic counseling and clinical care for affected families.
  • The International Premutation Conference provided a platform to consolidate current knowledge on FMR1 premutation and its associated conditions.